LUTS and sexual dysfunction: Implications for management of BPH

J van Moorselaar

doi:10.1016/j.eursup.2003.11.004

LUTS and sexual dysfunction: Implications for management of BPH

J van Moorselaar^*

^*Corresponding author for this work

University of Groningen

Research output: Contribution to journal › Article › Academic › peer-review

9 Citations (Scopus)

Abstract

Objectives: To summarise currently available data describing the impact of surgical and pharmacological treatments for lower urinary tract symptoms (LUTS) on male sexual function. To compare treatment options and outline implications for the management of this patient group.

Methods: Key published studies and newly emergent assessments evaluating individual treatments for benign prostatic hyperplasia (BPH) and/or LUTS were reviewed.

Results: Differences exist between available treatment options for LUTS with respect to impact on sexual function. Surgical procedures, including minimally invasive treatments, are associated with ejaculation and erectile dysfunction. Differences between classes of drug treatments are also evident; alpha(1)-adrenoceptor blockers demonstrate the least adverse effects on sexual function.

Conclusions: Preservation of sexual function is important in the maintenance of quality of life for ageing male patients with LUTS, and should be considered in physicians' treatment decisions. Potential effects of treatment options on sexual function should be discussed with patients before starting therapy. (C) 2003 Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	13-20
Number of pages	8
Journal	European urology supplements
Volume	2
Issue number	10
DOIs	https://doi.org/10.1016/j.eursup.2003.11.004
Publication status	Published - Dec-2003
Event	18th Congress of the EAU - , Spain Duration: 15-Mar-2003 → …

Keywords

BPH
LUTS
sexual dysfunction
alpha(1)-blockers
5 alpha-reductase inhibitors
BENIGN PROSTATIC HYPERPLASIA
URINARY-TRACT SYMPTOMS
QUALITY-OF-LIFE
PHASE-III MULTICENTER
ALFUZOSIN 10 MG
LONG-TERM
ALPHA(1A)-ADRENOCEPTOR ANTAGONIST
TRANSURETHRAL RESECTION
LASER PROSTATECTOMY
CONTROLLED TRIAL

Access to Document

10.1016/j.eursup.2003.11.004

Handle.net

Persistent link

Cite this

@article{ca440f14f25844e5a181f4fee57cf75f,

title = "LUTS and sexual dysfunction: Implications for management of BPH",

abstract = "Objectives: To summarise currently available data describing the impact of surgical and pharmacological treatments for lower urinary tract symptoms (LUTS) on male sexual function. To compare treatment options and outline implications for the management of this patient group.Methods: Key published studies and newly emergent assessments evaluating individual treatments for benign prostatic hyperplasia (BPH) and/or LUTS were reviewed.Results: Differences exist between available treatment options for LUTS with respect to impact on sexual function. Surgical procedures, including minimally invasive treatments, are associated with ejaculation and erectile dysfunction. Differences between classes of drug treatments are also evident; alpha(1)-adrenoceptor blockers demonstrate the least adverse effects on sexual function.Conclusions: Preservation of sexual function is important in the maintenance of quality of life for ageing male patients with LUTS, and should be considered in physicians' treatment decisions. Potential effects of treatment options on sexual function should be discussed with patients before starting therapy. (C) 2003 Elsevier B.V. All rights reserved.",

keywords = "BPH, LUTS, sexual dysfunction, alpha(1)-blockers, 5 alpha-reductase inhibitors, BENIGN PROSTATIC HYPERPLASIA, URINARY-TRACT SYMPTOMS, QUALITY-OF-LIFE, PHASE-III MULTICENTER, ALFUZOSIN 10 MG, LONG-TERM, ALPHA(1A)-ADRENOCEPTOR ANTAGONIST, TRANSURETHRAL RESECTION, LASER PROSTATECTOMY, CONTROLLED TRIAL",

author = "\{van Moorselaar\}, J",

year = "2003",

month = dec,

doi = "10.1016/j.eursup.2003.11.004",

language = "English",

volume = "2",

pages = "13--20",

journal = "European urology supplements",

issn = "1569-9056",

publisher = "ELSEVIER SCIENCE BV",

number = "10",

note = "18th Congress of the EAU ; Conference date: 15-03-2003",

}

TY - JOUR

T1 - LUTS and sexual dysfunction

T2 - 18th Congress of the EAU

AU - van Moorselaar, J

PY - 2003/12

Y1 - 2003/12

N2 - Objectives: To summarise currently available data describing the impact of surgical and pharmacological treatments for lower urinary tract symptoms (LUTS) on male sexual function. To compare treatment options and outline implications for the management of this patient group.Methods: Key published studies and newly emergent assessments evaluating individual treatments for benign prostatic hyperplasia (BPH) and/or LUTS were reviewed.Results: Differences exist between available treatment options for LUTS with respect to impact on sexual function. Surgical procedures, including minimally invasive treatments, are associated with ejaculation and erectile dysfunction. Differences between classes of drug treatments are also evident; alpha(1)-adrenoceptor blockers demonstrate the least adverse effects on sexual function.Conclusions: Preservation of sexual function is important in the maintenance of quality of life for ageing male patients with LUTS, and should be considered in physicians' treatment decisions. Potential effects of treatment options on sexual function should be discussed with patients before starting therapy. (C) 2003 Elsevier B.V. All rights reserved.

AB - Objectives: To summarise currently available data describing the impact of surgical and pharmacological treatments for lower urinary tract symptoms (LUTS) on male sexual function. To compare treatment options and outline implications for the management of this patient group.Methods: Key published studies and newly emergent assessments evaluating individual treatments for benign prostatic hyperplasia (BPH) and/or LUTS were reviewed.Results: Differences exist between available treatment options for LUTS with respect to impact on sexual function. Surgical procedures, including minimally invasive treatments, are associated with ejaculation and erectile dysfunction. Differences between classes of drug treatments are also evident; alpha(1)-adrenoceptor blockers demonstrate the least adverse effects on sexual function.Conclusions: Preservation of sexual function is important in the maintenance of quality of life for ageing male patients with LUTS, and should be considered in physicians' treatment decisions. Potential effects of treatment options on sexual function should be discussed with patients before starting therapy. (C) 2003 Elsevier B.V. All rights reserved.

KW - BPH

KW - LUTS

KW - sexual dysfunction

KW - alpha(1)-blockers

KW - 5 alpha-reductase inhibitors

KW - BENIGN PROSTATIC HYPERPLASIA

KW - URINARY-TRACT SYMPTOMS

KW - QUALITY-OF-LIFE

KW - PHASE-III MULTICENTER

KW - ALFUZOSIN 10 MG

KW - LONG-TERM

KW - ALPHA(1A)-ADRENOCEPTOR ANTAGONIST

KW - TRANSURETHRAL RESECTION

KW - LASER PROSTATECTOMY

KW - CONTROLLED TRIAL

U2 - 10.1016/j.eursup.2003.11.004

DO - 10.1016/j.eursup.2003.11.004

M3 - Article

SN - 1569-9056

VL - 2

SP - 13

EP - 20

JO - European urology supplements

JF - European urology supplements

IS - 10

Y2 - 15 March 2003

ER -

LUTS and sexual dysfunction: Implications for management of BPH

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this